Related Experiment Video
Updated: Jan 17, 2026
07:47
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
2.2K
Multi-omics integrated analysis identifies key biomarkers for hepatocellular carcinoma
Tao Xiong1, Yumin Zhang2, Xiangqiang Liu1
1School of Clinical Medicine, Shandong Second Medical University, Weifang, Shandong, People's Republic of China.
Medicine
|September 24, 2025
Summary
Researchers identified Cornichon Family Member 4 (CNIH4) as a key biomarker for hepatocellular carcinoma (liver cancer). This finding could lead to new diagnostic tools and therapeutic targets for this aggressive disease.
Area of Science:
- Oncology
- Genomics
- Biochemistry
Background:
- Hepatocellular carcinoma (HCC) has high malignancy and poor prognosis, with recurrence rates up to 70% in advanced stages.
- Early diagnosis is challenging, as less than 20% of patients are detected in early stages, leading to low 5-year survival rates (<10%).
Purpose of the Study:
- To identify novel and effective biomarkers for hepatocellular carcinoma (HCC).
- To analyze potential etiological factors and explore new treatment strategies for HCC using multi-omics approaches.
Main Methods:
- Utilized transcriptome-wide association studies, Mendelian randomization, weighted correlation network analysis, machine learning, and spatial transcriptomics.
- Incorporated molecular docking, virtual screening, and phenome-wide association studies to analyze Cornichon Family Member 4 (CNIH4).
Main Results:
- Confirmed the heterogeneity of Cornichon Family Member 4 (CNIH4) in HCC.
- Established CNIH4's relevance to the immune microenvironment, cancer-immunity cycle, and intratumoral infections.
- Identified small-molecule compounds interacting with CNIH4 and analyzed potential side effects.
Conclusions:
- Cornichon Family Member 4 (CNIH4) is a key biomarker for hepatocellular carcinoma (HCC), integrating transcriptome, spatial transcriptome, infection, and immune data.
- CNIH4 shows potential as a therapeutic target for HCC.
- Further clinical validation is required to confirm these findings.
